Vera Therapeutics’ (VERA) Neutral Rating Reaffirmed at Wedbush

Vera Therapeutics (NASDAQ:VERA)‘s stock had its “neutral” rating reaffirmed by equities researchers at Wedbush in a research note issued on Monday,Benzinga reports. They presently have a $34.00 price target on the stock. Wedbush’s target price points to a potential upside of 7.49% from the company’s current price.

A number of other equities research analysts have also commented on the company. Jefferies Financial Group reiterated a “buy” rating and issued a $60.00 price target on shares of Vera Therapeutics in a research report on Tuesday, June 2nd. William Blair reissued an “outperform” rating on shares of Vera Therapeutics in a research report on Tuesday, June 2nd. Guggenheim lifted their target price on shares of Vera Therapeutics from $56.00 to $76.00 and gave the stock a “buy” rating in a research note on Wednesday, July 8th. Bank of America upped their target price on Vera Therapeutics from $65.00 to $70.00 and gave the company a “buy” rating in a research report on Tuesday, July 7th. Finally, Needham & Company LLC set a $125.00 price target on Vera Therapeutics in a research note on Wednesday, July 8th. One investment analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, Vera Therapeutics currently has a consensus rating of “Moderate Buy” and an average price target of $81.15.

Vera Therapeutics Stock Performance

Shares of VERA stock opened at $31.63 on Monday. The firm has a market capitalization of $2.28 billion, a price-to-earnings ratio of -5.40 and a beta of 0.92. The company has a current ratio of 10.92, a quick ratio of 10.92 and a debt-to-equity ratio of 0.18. The business’s 50-day moving average price is $36.38 and its 200-day moving average price is $38.45. Vera Therapeutics has a 12 month low of $21.15 and a 12 month high of $56.05.

Vera Therapeutics (NASDAQ:VERA) last released its quarterly earnings data on Monday, August 10th. The company reported ($1.52) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.58) by $0.06. During the same period last year, the company posted ($1.20) earnings per share. Equities research analysts forecast that Vera Therapeutics will post -6.46 EPS for the current year.

Insider Buying and Selling at Vera Therapeutics

In other news, CEO Marshall Fordyce sold 46,250 shares of the firm’s stock in a transaction that occurred on Tuesday, July 7th. The shares were sold at an average price of $42.30, for a total transaction of $1,956,375.00. Following the completion of the sale, the chief executive officer owned 151,994 shares in the company, valued at $6,429,346.20. This trade represents a 23.33% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 15.90% of the stock is owned by corporate insiders.

Institutional Trading of Vera Therapeutics

Large investors have recently bought and sold shares of the company. Los Angeles Capital Management LLC purchased a new position in shares of Vera Therapeutics in the fourth quarter worth about $46,000. Aster Capital Management DIFC Ltd purchased a new stake in shares of Vera Therapeutics during the 4th quarter valued at approximately $71,000. Quantbot Technologies LP bought a new stake in Vera Therapeutics during the 2nd quarter valued at $51,000. Sandia Investment Management LP purchased a new stake in shares of Vera Therapeutics during the fourth quarter worth $127,000. Finally, Mirae Asset Global Investments Co. Ltd. boosted its holdings in shares of Vera Therapeutics by 25.9% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,106 shares of the company’s stock worth $157,000 after acquiring an additional 639 shares during the period. 99.21% of the stock is owned by hedge funds and other institutional investors.

About Vera Therapeutics

Vera Therapeutics is a clinical-stage biotechnology company focused on developing novel immunotherapies that harness the body’s own regulatory T cells to treat autoimmune and inflammatory diseases. By leveraging a proprietary protein engineering platform, the company designs Treg-selective cytokine variants intended to restore immune balance and provide targeted, disease-modifying effects. Its pipeline comprises multiple preclinical and clinical candidates aimed at indications characterized by chronic inflammation and autoimmunity.

Founded in 2018 and headquartered in Cambridge, Massachusetts, Vera Therapeutics collaborates with leading academic and research institutions to advance its development programs.